Hepatitis A vaccine (inactivated) strain HM175 1440 UNT/ML [Havrix]
RxNorm 798365

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 798365 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: hepatitis A vaccine (inactivated) strain HM175 1440 UNT/ML [Havrix].

The following semantic concepts and normalized strings are associated with this clinical entity:

SBDC
Hepatitis A vaccine (inactivated) strain HM175 1440 UNT/ML [Havrix]
AUI:12305512
View

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

SBDCPrescribable

Semantic Branded Drug Component (SBDC):
Hepatitis A vaccine (inactivated) strain HM175 1440 UNT/ML [Havrix]
(Atom ID: 12305512)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
hepatitis A vaccine (inactivated) strain HM175 1440 UNT/ML [Havrix]
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
798365
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12305512
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SBDC
Semantic Branded Drug Component (Ingredient + Strength + Brand Name)
Source Code
798365
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Patient Education

Hepatitis A Vaccine


Why get vaccinated against hepatitis A? Hepatitis A is a serious liver disease. It is caused by the hepatitis A virus (HAV). HAV is spread from person to person through contact with the feces (stool) of people who are infected, which can easily happen if someone does not wash his or her hands properly. You can also get hepatitis A from food, water, or objects contaminated with HAV. Symptoms of hepatitis A can include the following: fever, fatigue, loss of appetite, nausea, vomiting, and/or joint pain severe stomach pains and diarrhea (mainly in children) jaundice (yellow skin or eyes, dark urine, clay-colored bowel movements) These symptoms usually appear 2 to 6 weeks after exposure and usually last less than 2 months, although some people can be ill for as long as 6 months. If you have hepatitis A you may be too ill to work. Children often do not have symptoms, but most adults do. You can spread HAV without having symptoms. Hepatitis A can cause liver failure and death, although this is rare and occurs more commonly in persons 50 years of age or older and persons with other liver diseases, such as hepatitis B or C. Hepatitis A vaccine can prevent hepatitis A. Hepatitis A vaccines were recommended in the United States beginning in 1996. Since then, the number of cases reported each year in the United States has dropped from around 31,000 cases to fewer than 1,500 cases.
[Learn More]


* Please review the disclaimer below.